📊 PTIXW Key Takeaways
Is Protagenic Therapeutics, Inc.new (PTIXW) a Good Investment?
Protagenic Therapeutics exhibits critical financial distress with negative stockholders equity of -$2.4M, zero revenue generation despite being in the pharmaceutical sector, and a severe liquidity crisis evidenced by a 0.34x current ratio. With operating cash burn of -$3.1M annually against only $2.2M in cash, the company has insufficient runway and faces imminent solvency challenges.
Protagenic Therapeutics, Inc.new Key Strengths (PTIXW)
- Maintains $2.2M in cash providing short-term operational runway
- Still maintains assets of $4.4M that could theoretically be liquidated
- Operating in pharmaceutical sector with potential IP or research pipeline (though not generating revenue)
PTIXW Stock Risks: Protagenic Therapeutics, Inc.new Investment Risks
- Negative stockholders equity of -$2.4M indicates technical insolvency
- Zero revenue with annual operating loss of -$4.4M indicates no viable business model
- Critical liquidity crisis: current ratio of 0.34x; liabilities 1.5x total assets
- Negative free cash flow of -$3.2M annually depletes $2.2M cash in under 12 months
- Return on assets of -83.9% indicates severe asset inefficiency
- No insider activity in 90 days suggests lack of confidence from management
- High probability of bankruptcy, debt restructuring, or highly dilutive financing
Key Metrics to Watch
- Cash balance and monthly burn rate
- Any revenue generation or partnership announcements
- Operating cash flow improvements or deterioration
- Stockholders equity trend toward solvency
- SEC filings for bankruptcy, restructuring, or capital raise announcements
Protagenic Therapeutics, Inc.new (PTIXW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PTIXW Profit Margin, ROE & Profitability Analysis
PTIXW vs Healthcare Sector: How Protagenic Therapeutics, Inc.new Compares
How Protagenic Therapeutics, Inc.new compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Protagenic Therapeutics, Inc.new Stock Overvalued? PTIXW Valuation Analysis 2026
Based on fundamental analysis, Protagenic Therapeutics, Inc.new has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Protagenic Therapeutics, Inc.new Balance Sheet: PTIXW Debt, Cash & Liquidity
PTIXW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Protagenic Therapeutics, Inc.new's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.15 indicates the company is currently unprofitable.
PTIXW Revenue Growth, EPS Growth & YoY Performance
PTIXW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | N/A | -$324.4K | $-0.16 |
| Q2 2026 | N/A | -$324.4K | $-0.11 |
| Q1 2025 | N/A | -$1.4M | $-2.75 |
| Q3 2024 | N/A | -$640.8K | $-0.14 |
| Q2 2024 | N/A | -$718.1K | $-0.28 |
| Q1 2024 | N/A | -$718.1K | $-0.17 |
| Q3 2023 | N/A | -$666.7K | $-0.21 |
| Q2 2023 | N/A | -$666.7K | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Protagenic Therapeutics, Inc.new Dividends, Buybacks & Capital Allocation
PTIXW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Protagenic Therapeutics, Inc.new (CIK: 0001022899)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PTIXW
What is the AI rating for PTIXW?
Protagenic Therapeutics, Inc.new (PTIXW) has an AI grade of D with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PTIXW's key strengths?
Claude: Maintains $2.2M in cash providing short-term operational runway. Still maintains assets of $4.4M that could theoretically be liquidated.
What are the risks of investing in PTIXW?
Claude: Negative stockholders equity of -$2.4M indicates technical insolvency. Zero revenue with annual operating loss of -$4.4M indicates no viable business model.
What is PTIXW's revenue and growth?
Protagenic Therapeutics, Inc.new reported revenue of $0.0.
Does PTIXW pay dividends?
Protagenic Therapeutics, Inc.new does not currently pay dividends.
Where can I find PTIXW SEC filings?
Official SEC filings for Protagenic Therapeutics, Inc.new (CIK: 0001022899) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PTIXW's EPS?
Protagenic Therapeutics, Inc.new has a diluted EPS of $-1.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PTIXW's fundamental grade?
Based on our AI fundamental analysis in June 2026, Protagenic Therapeutics, Inc.new has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PTIXW stock overvalued or undervalued?
Valuation metrics for PTIXW: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PTIXW's AI grade for 2026?
Our dual AI analysis gives Protagenic Therapeutics, Inc.new a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PTIXW's free cash flow?
Protagenic Therapeutics, Inc.new's operating cash flow is $-3.1M, with capital expenditures of $149.8K.
How does PTIXW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.34 (avg: 2).